Therapeutic Product Immunogenicity Community

 View Only

New AAPS Journal article of possible community interest

  • 1.  New AAPS Journal article of possible community interest

    Posted 10-16-2023 12:21
    Addressing domain specificity in the development of a cell-based binding assay for the detection of neutralizing antibodies against a CD47xPD-L1 bispecific antibody

    https://link.springer.com/article/10.1208/s12248-023-00856-9

    PF-07257876 is a bispecific antibody being developed for the treatment of certain advanced or metastatic solid tumors. To support clinical development of PF-07257876, neutralizing antibody (NAb) assays were developed as part of a tiered immunogenicity testing approach. Because PF-07257876 targets both CD47 and PD-L1, determination of domain specificity of a NAb response may provide additional insight relating to PK, efficacy, and safety. Due to limitations of functional cell systems, two cell-based binding assays were developed using electrochemiluminescence to detect domain-specific NAb. While both NAb assays utilized a cell-based binding approach and shared certain requirements, such as sensitivity and tolerance to potentially interfering substances, the development of each assay faced unique challenges. Among the hurdles encountered, achieving drug tolerance while preserving domain specificity for CD47 proved particularly challenging. Consequently, a sample pretreatment procedure to isolate NAb from potentially interfering substances was necessary. The sample pretreatment procedure developed was based on a bead-extraction and acid dissociation (BEAD) approach. However, the use of the standard BEAD approach with whole drug to capture NAb resulted in loss of NAb detection under certain circumstances. Specifically, mock samples containing a mixture of NAb positive controls against both binding domains of the bispecific antibody produced false-negative results in the cell-based binding assay. An adaptation made to the standard BEAD approach restored domain-specific NAb detection, while also contributing to an assay sensitivity of 1 µg/mL in the presence of a clinically relevant drug tolerance level of up to 400 µg/mL.

    To view the full article through your AAPS membership:

    Go to https://www.aaps.org/education-and-research/journals/the-aaps-journal. Click or tap if you trust this link." rel="noopener">https://www.aaps.org/education-and-research/journals/the-aaps-journal 

    Enter your AAPS credentials

    Click "Member Access to Journals"

    Click on the The AAPS Journal cover.

    Copy and paste the url into the "Search" box, and click search

    The full article should appear.

    Follow The AAPS Journal via Twitter: https://twitter.com/theaapsjournal

    and by Linkedin,  https://www.linkedin.com/showcase/theaapsjournal/



    ------------------------------
    Ho-Leung Fung Ph.D., FAAPS
    Editor-in-Chief
    University at Buffalo
    Sarasota FL
    [email protected]

    Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
    ------------------------------